Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1452360 | 0.88 | CHRNB2 (0.32) | CHRNB2CHRNA4CYP1A2CYP2A6 | |
| SCHEMBL18489608 | 0.88 | HTT (0.30) | — | |
| SCHEMBL1452653 | 0.81 | KDM1A (0.31) | CHRNB2CHRNA4 | |
| SCHEMBL2944071 | 0.79 | PTGDR2 (0.40) | — | |
| SCHEMBL1453356 | 0.78 | ALDH1A1 (0.33) | — | |
| SCHEMBL1453774 | 0.78 | — | — | |
| SCHEMBL1454072 | 0.78 | LMNA (0.36) | — | |
| SCHEMBL1454531 | 0.78 | ACHE (0.37) | CYP1A2CYP2A6 | |
| SCHEMBL1453942 | 0.77 | CYP1A2 (0.36) | CHRNB2CHRNA4CYP1A2 | |
| SCHEMBL1454121 | 0.77 | HTR2C (0.34) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910783-B2 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| EP-1034190-B1 | POLYMERIZATION CATALYST FOR OLEFIN MONOMERS | LG CHEMICAL LTD (KR) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135596-A1 | Preparation of substituted bridged indenyl and related ligands | SP1, TTL, TTLL12 | CHRNB2 2516/4885CHRNA4 2611/4885CYP1A2 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.